Medical Developments grows Penthrox market share in UK and Ireland
Shares in Medical Developments (ASX: MVP) initially surged more than 5% in afternoon trading after the group announced promising uptake of its Penthrox product (often referred to as the green whistle) in the United Kingdom.
However, the company’s share price quickly retraced, perhaps indicating that investors are mainly focused on entry into mainland Europe where the group has 22 applications submitted to the United Kingdom’s Medicine and Healthcare Products Regulatory Agency (MHRA) under the decentralised procedure in November 2016.
Medical Developments share price ran strongly in the early part of 2016 more than doubling from less than $3.00 to hit an all-time high of $6.85, but in the second half they retraced to strike a six month low of $4.12 in December. In the last month they have recovered slightly to trade in a tight range between $5.00 and $5.50.
It should be noted that share trading patterns should not be used as the basis for an investment as they may not be replicated. Those considering this stock should seek independent financial advice.
From an operational perspective, Chief Executive, Jon Sharman said, “MVP expects approvals will be received to sell Penthrox in these 22 countries and another 15 countries via the National Approval process during the course of 2017 and 2018”.
The company’s success in the UK has been built around use of the fast onset, non-opioid analgesic in hospitals and trauma centres, effectively replicating its applications in Australia where it has been used safely and effectively for more than 30 years with more than 5 million units sold.
Galen, the entity appointed by MVP to supply Penthrox in the United Kingdom and Ireland has made good progress, and 34 hospitals have approved and are now using Penthrox.
There are 11 major trauma centre hospitals in the UK, four of which have approved and are using Penthrox.
Medical Developments expects further uptake of the product in this area with Sharman saying, “Recent success in the major trauma centres in the UK and Ireland is very encouraging and the feedback from the market is very positive, leading us to expect a number of additional hospital and ambulance trusts will approve Penthrox in the coming months”.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Longhou Capital Markets Pty Ltd (AFSL No. 292464). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.